BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, when the CML cell line K562 is selected for Imatinib resistance, the resultant cell line (K562R) has elevated Lyn levels and kinase activity, as apposed to BCR-Abl mutations; their sensitivity to this drug is regained upon down-regulation of Lyn [76].